New radiation therapy shows promise for Hard-to-Treat gut cancers
NCT ID NCT07404176
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new radioactive drug called Terbium-161 DOTATATE in 20 people with advanced neuroendocrine tumors that have spread and stopped responding to standard treatment. The drug delivers radiation directly to cancer cells, aiming to control the disease with fewer side effects. Researchers will measure how well it shrinks or stabilizes tumors and monitor safety through blood tests and scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Terbium-161 DOTATATE (a radioactive drug that targets cancer cells)
What this could lead to
If successful, this could offer a new treatment option for patients with neuroendocrine tumors that no longer respond to current therapies, potentially with fewer side effects.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug is experimental, and its safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
RECRUITINGNavi Mumbai, Maharashtra, 410210, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tata Memorial Hospital, Mumbai, India
RECRUITINGMumbai, Maharashtra, 400012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••